Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT ID: NCT03394755

Last Updated: 2023-04-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-19
• Study Completion Date: 2019-09-25

Brief Summary

The study evaluates the safety and potential early signals of efficacy of allogeneic Thrombosomes in bleeding thrombocytopenic patients

Detailed Description

The primary objective of the present study was to assess the safety of increasing dose levels of Thrombosomes in bleeding patients with thrombocytopenia. The secondary objective was to explore early signals of clinical efficacy of Thrombosomes in this population. The secondary objectives included: 1) Evaluation of the impact on WHO (World Health Organization) bleeding scores at various timepoints; 2) number and type of blood products infused through day 6 follow-up period; and 3) post hoc analysis of hematology, coagulation, and chemistry.

Conditions

Thrombocytopenia; Hematologic Diseases; Bone Marrow Aplasia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

9.45 x 10^7 Thrombosomes/kg

Cohort 1

Group Type: EXPERIMENTAL

Thrombosomes

Intervention Type: BIOLOGICAL

Freeze-dried platelets

1.89 x 10^8 Thrombosomes/kg

Cohort 2

Group Type: EXPERIMENTAL

Thrombosomes

Intervention Type: BIOLOGICAL

Freeze-dried platelets

3.78 x10^8 Thrombosomes/kg

Cohort 3

Group Type: EXPERIMENTAL

Thrombosomes

Intervention Type: BIOLOGICAL

Freeze-dried platelets

Interventions

Thrombosomes

Freeze-dried platelets

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Adults up to 74 y/o with any of following: acute leukemia (ALL or AML), myelodysplasia, aplasia, and/or therapy (chemotherapy or radiation) induced bone marrow aplasia or hypoplasia with thrombocytopenia (platelet count ≥ 5,000 and ≤ 70,000/μL) for a minimum of 2 days. May include bone marrow transplant or peripheral or cord blood stem cell recipients, but not subjects with Graft-vs-Host disease.
• Hospitalized patients (or willing to be hospitalized for 24 hours after Rx) with Modified WHO Grade 1 (subset) or Grade 2 Bleeding Score or at risk for same within 4 weeks of screening. The Grade 1 subset includes patients who have either epistaxis, hematuria, oral petechiae, or bleeding at invasive or other wound sites.
• No platelet inhibitor drugs within 5 days prior to infusion and through Day 6 follow-up period.

Exclusion Criteria

• History or condition related to thrombosis, embolism or vascular occlusion/ischemia, including but not limited to: transient ischemic attack, stroke, myocardial infarction, stent placement, valve replacement and/or repair
• Currently with an active acute infection, or suspected infection, a single oral temperature of ≥ 101° F or a temperature of ≥ 100.4°F sustained over a 1 h period in past 24 h. Subjects on prophylactic antibiotics are not excluded from study
• Coagulopathy or receiving anticoagulants that result in PT (prothrombin time) or aPTT (activated partial thromboplastin time) values greater than 1.3 X upper limit of normal or elevated D-dimer of decreased fibrinogen
• History of any inherited coagulation or platelet function, disorder or ITP (idiopathic thrombocytopenic purpura), TTP (thrombotic thrombocytopenic purpura), or HUS (hemolytic-uremic syndrome)
• Receipt of tranexamic acid or other antifibrinolytics within 48 hrs prior to infusion
• Treatment with an investigational drug within 1 month of infusion, other than for treatment of their underlying disease

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Department of Health and Human Services

FED

Sponsor Role: collaborator

Cellphire Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Fitzpatrick

Role: STUDY_DIRECTOR

Cellphire Therapeutics, Inc.

Locations

City of Hope

Duarte, California, United States

Georgetown University Hospital

Washington D.C., District of Columbia, United States

University of Michigan

Ann Arbor, Michigan, United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Hoxworth Blood Center/University of Cincinnati

Cincinnati, Ohio, United States

MD Anderson Cancer Center

Houston, Texas, United States

Haukeland University Hospital

Bergen, , Norway

Countries

United States; Norway

References

Ohanian M, Cancelas JA, Davenport R, Pullarkat V, Hervig T, Broome C, Marek K, Kelly M, Gul Z, Rugg N, Nestheide S, Kinne B, Szczepiorkowski Z, Kantarjian H, Pehta J, Biehl R, Yu A, Aung F, Antebi B, Fitzpatrick GM. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. Am J Hematol. 2022 Mar 1;97(3):256-266. doi: 10.1002/ajh.26403. Epub 2021 Dec 23.

Reference Type: BACKGROUND

PMID: 34748664 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2017-1

Identifier Type: -

Identifier Source: org_study_id